Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
March 2025
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
Lancet Rheumatol, 2025. Epub ahead of print
Carter et al. review the clinical and mechanistic development of B-cell targeted therapies over the last two decades in autoimmune rheumatic diseases. B-cell depletion depth, repopulation dynamics, and immunogenicity determine long-term efficacy and inform the rationale for emerging
dual-targeted approaches, particularly in systemic lupus erythematosus where belimumab and rituximab combinations show potential to mitigate relapse driven by BAFF.
February 2025
Efficacy and safety of obinutuzumab in active lupus nephritis
NEJM, 2025. Epub ahead of print. DOI: 10.1056/NEJMoa2410965
Furie et al. demonstrated that obinutuzumab plus standard therapy significantly improved complete renal response at Wk76 compared with placebo. No unexpected safety signals were identified, though infections and COVID-19-related events were more frequent in the obinutuzumab group.
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: A real-world multicentre study
Lupus Science & Medicine, 2025;12:e001296 DOI:10.1136/lupus-2024-001296
Chen et al. demonstrated that sequential treatment with belimumab or telitacicept following rituximab (RTX) is a potential therapeutic approach for treating refractory LN. Major AEs included immunoglobin deficiency, respiratory tract infections and urinary tract infections, which are consistent with previous studies.